9 patents currently held
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2033. from the record
Of the 3 now held by other companies, 3 name Kyoto University as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2033
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2033 · Medium confidence
Also notable
Ends no later than Jan 2034 · Medium confidence
Also notable
Ends Feb 2034 · High confidence
Methods of Treating a Tauopathy
US 8,926,974
The most cited patent in this portfolio, cited by 92 later US patents, top 5% of utility patents granted in 2015 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Methods of Treating a Tauopathy
US 8,980,270
Cited by 32 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Tau Peptides, Anti-Tau Antibodies, and Methods of Use Thereof
US 10,400,018
Cited by 21 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2034.
Formerly held, still cited
Notable
Ends Sep 2029 · High confidence
The most cited patent in this portfolio, cited by 105 later US patents, top 10% of utility patents granted in 2012 in our data. Protection runs to 2029.
now held by Kyoto University
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Methods of Treating a Tauopathy (US 9,051,367) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Tau Peptides, Anti-Tau Antibodies, and Methods of Use Thereof (US 10,400,018) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods of Treating a Tauopathy (2014) | 5 in force | to Jan 2034 |
| Methods of Treating a Tauopathy (2013) | 3 in force | to Aug 2033 |
| Tau Peptides, Anti-Tau Antibodies, and Methods of Use Thereof | 1 in force | to Feb 2034 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,926,974 | Methods of Treating a Tauopathy In force · Medium confidence | In force | Medium confidence | |
| US 9,567,395 | Methods of Treating a Tauopathy In force · Medium confidence | In force | Medium confidence | |
| US 10,040,847 | Methods of Treating a Tauopathy In force · Medium confidence | In force | Medium confidence | |
| US 8,980,270 | Methods of Treating a Tauopathy In force · Medium confidence | In force | Medium confidence | |
| US 8,980,271 | Methods of Treating a Tauopathy In force · Medium confidence | In force | Medium confidence | |
| US 9,051,367 | Methods of Treating a Tauopathy In force · Medium confidence | In force | Medium confidence | |
| US 9,447,180 | Methods of Treating a Tauopathy In force · Medium confidence | In force | Medium confidence | |
| US 9,777,058 | Methods of Treating a Tauopathy In force · Medium confidence | In force | Medium confidence | |
| US 10,400,018 | Tau Peptides, Anti-Tau Antibodies, and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 3 patents in force now held by others · 1 patent ended · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.